ライフサイエンスコーパス: aphakia

1 atients with posttraumatic and postoperative aphakia.

2 n before age 7 months has no advantages over aphakia.

3 nt secondary IOL implantation for unilateral aphakia.

4 result in significant periods of uncorrected aphakia.

5 opmental defect that finally progresses into aphakia.

6 pecification and organogenesis, resulting in aphakia.

7 lantation in posttraumatic and postoperative aphakia.

8 a (141 eyes, group 1), post-cataract surgery aphakia (122 eyes, group 2), and in cases in which penet

9 ormed RPICIOL implantation in post-traumatic aphakia (141 eyes, group 1), post-cataract surgery aphak

10 optic atrophy (6.4%), phthisis bulbi (6.4%), aphakia (5.6%) and glaucoma (5.2%).

11 who underwent secondary IOL implantation for aphakia after congenital cataract surgery at L. V. Prasa

12 Eyes with aphakia after surgery for traumatic cataracts and other

13 Mouse aphakia (ak) is a recessive phenotype that spontaneously

14 Here, we demonstrate that Pitx3-deficient aphakia (ak) mice, which have been shown previously to e

15 The recessive aphakia (ak) mouse mutant is characterized by bilateral

16 em (LCS) makes use of a mutant mouse strain, aphakia (ak), homozygotes of which fail to develop an oc

17 provides the first direct evidence that the aphakia allele of Pitx3 is a hypomorph and that Pitx3 is

18 tion is approximately 7% more expensive than aphakia and CL correction.

19 ater understanding of the natural history of aphakia and pseudophakia have changed the approach to th

20 iridocorneal endothelial syndrome, aniridia, aphakia, and anterior chamber intraocular lenses, among

21 fferences between eyes having primary IOL vs aphakia, and optimal timing of unilateral congenital cat

22 lana vitrectomy; secondary implantations for aphakia; and iris suture fixation at primary cataract ex

23 rating keratoplasty, ICE syndrome, aniridia, aphakia, complex anterior chambers with anterior chamber

24 that a cell autonomous defect underlies the aphakia condition assures that lenses generated through

25 To assess the constants and formula for aphakia correction with iris-claw IOLs to achieve the be

26 ris-fixated claw IOL, ACIOL implantation for aphakia has regained popularity.

27 Recent studies of mouse mutant aphakia have implicated the homeobox gene Pitx3 in the s

28 The aphakia homozygous mouse is characterized by small eyes

29 tients with glaucoma, cataract, and surgical aphakia in better coping with the impact of these condit

30 ular lenses are a well-accepted treatment of aphakia in children 2 years of age and older, with many

31 Options available to treat aphakia in children with inadequate support for posterio

32 tion in Foxe3 that causes congenital primary aphakia in humans marks an important milestone.

33 WCLs) for the optical treatment of infantile aphakia in humans.

34 trial comparing the treatment of unilateral aphakia in patients under 7 months of age with a primary

35 Contact lenses were used to correct aphakia in patients who did not receive IOLs.

36 erally sutured intraocular lenses to correct aphakia in pediatric patients.

37 , presence of epiretinal membrane (ERM), and aphakia in the study eye.

38 Congenital primary aphakia is a rare developmental disease in which the len

39 ay also be appropriate when the patient with aphakia is young and has a relatively long life expectan

40 Aphakia (lack of lens) is a rare human congenital disord

41 , we took advantage of PITx3-deficient mice (aphakia mice), in which DA in the dorsal striatum is red

42 When transplanted into PD model animals, aphakia mice, and 6-OHDA-lesioned rats, mDA NPs differen

43 that the abnormal ocular development in the aphakia mouse is due to the deletion upstream of the Pit

44 Our results from the Pitx3-deficient aphakia mouse suggest that pre-existing DA neurons modul

45 However, when we examined the aphakia mouse, which is deficient in nigrostriatal neuro

46 Pitx3 was mapped close to aphakia on mouse chromosome 19.

47 All eyes presented with aphakia or luxated or subluxated posterior chamber intra

48 amples include the glaucomas associated with aphakia or pseudophakia, neovascular glaucoma, and glauc

49 ination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month i

50 a make Pitx3 a strong candidate gene for the aphakia phenotype in the mouse and suggest a role for th

51 Exclusion criteria included aphakia, pseudophakia, late age-related macular degenera

52 ry causes than in patients being treated for aphakia resulting from other causes (71% vs 29%).

53 The indications were postsurgical aphakia, subluxated cataract, ectopia lentis, traumatic

54 tral corneal thickness (CCT) from the Infant Aphakia Treatment Study (IATS) patients at the 5-year ex

55 Fifty-seven infants in the Infant Aphakia Treatment Study (IATS) with a unilateral catarac

56 Infants enrolled in the Infant Aphakia Treatment Study (IATS).

57 lantation for infants enrolled in the Infant Aphakia Treatment Study (IATS).

58 The just completed Infant Aphakia Treatment Study aims to answer questions regardi

59 glaucoma suspect were created for the Infant Aphakia Treatment Study and applied for surveillance and

60 The Infant Aphakia Treatment Study enrolled 114 children; 57 were r

61 Results of the Infantile Aphakia Treatment Study have concluded that primary IOL

62 ars of age by a traveling examiner using the Aphakia Treatment Study HOTV protocol.

63 The Infant Aphakia Treatment Study is a randomized clinical trial w

64 The Infant Aphakia Treatment Study is a randomized, multicenter (n

65 The Infant Aphakia Treatment Study randomized 114 patients with uni

66 lysis of a randomized clinical trial (Infant Aphakia Treatment Study) of infants born from August 1,

67 Data came from the Infant Aphakia Treatment Study, a randomized clinical trial of

68 l of 114 infants were enrolled in the Infant Aphakia Treatment Study, a randomized, multi-center (12)

69 dverse events than reported in the Infantile Aphakia Treatment Study.

70 eived primary IOL implantation in the Infant Aphakia Treatment Study.

71 emoval in infancy, yet their relationship to aphakia vs primary intraocular lens (IOL) implantation r

72 Aphakia was due to eye trauma (19) or complicated catara

73 before the first visit when pseudophakia or aphakia was observed.

74 Those with pseudoexfoliation or aphakia were more likely to progress to blindness.

75 otal posterior capsulectomy, vitrectomy, and aphakia were once the standard of care, many physicians

76 ntation is the standard of care for treating aphakia when spectacle or contact lens correction is not

77 (n=12) clinical trial comparing treatment of aphakia with a primary IOL or contact lens in 114 infant

78 = 12), clinical trial comparing treatment of aphakia with a primary IOL or contact lens in 114 infant

79 cal trial comparing the optical treatment of aphakia with either primary IOL implantation (n = 57) or

80 rative complications, neonatal correction of aphakia with IOLs combined with EWCLs can lead to normal

81 The ideal intraocular lens in cases of aphakia without capsular support is debated.